Standout Papers

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half ... 1998 2026 2007 2016 2.1k
  1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. (1998)
    Peter McLaughlin, A.J. Grillo-López et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 21 from Science/Nature 61 standout
Sub-graph 1 of 19

Citing Papers

CAR immune cells: design principles, resistance and the next generation
2023 StandoutNature
Monoclonal Antibodies in Cancer Therapy
2020 Standout
1 intermediate paper

Works of Meyer R. Heyman being referenced

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
1998 Standout

Author Peers

Author Last Decade Papers Cites
Meyer R. Heyman 436 393 911 1394 1123 22 2.8k
Diying Shen 302 342 1137 1696 1182 33 3.0k
David Bodkin 228 742 708 1088 1312 25 3.0k
Isabelle Bence‐Bruckler 456 323 1333 1998 1410 61 3.4k
Charles W. Ross 257 215 526 1602 992 63 2.6k
Leonardo Flenghi 250 533 469 1449 865 35 2.7k
Tak Takvorian 949 218 889 1525 1081 57 2.9k
C. Varns 171 261 784 1460 980 9 2.4k
Joke W. Baars 635 342 494 880 923 52 2.3k
DG Maloney 344 560 870 1294 1081 35 3.1k
Raymond E. Felgar 264 235 524 872 474 38 2.7k

All Works

Loading papers...

Rankless by CCL
2026